Guanghui Hu

Company: Naki Therapeutics

Job title: Chief Executive Officer

Seminars:

Developing CAR-NK Therapies for Solid Tumors 12:00 pm

We are developing a “combination” CAR-NK therapy (integrating IL15 with anti-CD147 CAR-NK) that has shown a great promise in treating solid tumors in pre-clinical studies We have also developed a NK / CAR-NK cell expansion technology platform with great expansion efficiency and fidelityRead more

day: Day 2: Pre-Clinical & Translational